U.S. Viscosupplementation Market

U.S. Viscosupplementation Market Size

The viscosupplementation market size in the U.S. was valued at USD 2.3 billion in 2024. The U.S. market is forecasted to grow at a significant CAGR of 10.44% from 2025 to 2033 and be worth USD 5.62 billion by 2033 from USD 2.54 billion in 2025.

MARKET DRIVERS

The growing patient population suffering from osteoarthritis in the U.S. and increasing demand for non-surgical treatment are propelling the U.S. viscosupplementation market growth. According to the Centers for Disease Control and Prevention (CDC), an estimated 34.5 million adults in the United States suffer from osteoarthritis each year. People who suffer from osteoarthritis usually have less hyaluronic acid in the joints, leading to pain, stiffness, swelling, and difficulty in movement. In recent years, people have shown interest in non-surgical treatment due to fear of surgical procedures and expensive treatment costs. Increasing advancements in the development of hyaluronic acid-based therapies are further promoting the viscosupplementation market growth in the United States. The key market participants are focusing on developing a treatment with hyaluronic acid, which helps with fast relief from knee pain for every age group. In addition, researchers are increasing the number of different ways of treatment to slow down knee pain disorder expansion.

The increasing geriatric population is expected to fuel the growth of the viscosupplementation market in the U.S. during the forecast period. Nearly 100 million Americans suffer from knee pain, the second most common chronic pain in the United States. Knee pain can be caused due to diabetes, obesity, and other reasons. People 60 years of age are more likely to face severe knee problems and need treatment. Thus, the growing aging population suffering from severe knee pain is expected to generate demand for viscosupplementation. Furthermore, growing R&D activities, increasing investments by the U.S. government, favorable reimbursement policies, increasing product launches in the market, and a growing adoption rate of viscosupplementation in the U.S. are driving the market growth.

MARKET RESTRAINTS

The presence of alternative knee therapies is the major restrain of the market growth in the United States. Along with the high cost of Viscosupplementation treatment, a lack of awareness of Viscosupplementation and a lack of skilled professionals for the treatment in most hospitals are factors that hamper market growth. In addition, side effects after the treatment, such as pain, swelling, heat, and redness, challenge the U.S. market growth. In addition, alternative knee therapies, high costs associated with viscosupplementation, lack of awareness, and lack of skilled professionals hamper the market growth. In addition, side effects associated with the treatment, such as pain, swelling, heat, and redness are hindering the U.S. market expansion.

REGIONAL ANALYSIS

The U.S. plays a vital role in the global viscosupplementation market. In 2023, the U.S. market held a significant share of the North American region. The increasing number of product approvals by the FDA and growing healthcare spending by the U.S. population are favoring the viscosupplementation market in this country. In addition, the growing aging population in the U.S. is expected to boost the usage of viscosupplementation in the coming days. However, nearly 20% of people in the U.S. are aging more than 45 years and suffer from knee osteoarthritis.

On the other hand, the Canadian viscosupplementation market is expected to hold a considerable share of the North American market in the coming years. Recently, the Arthroscopy Association of Canada (AAC) published guidelines for treating knee pain. The viscosupplementation market participants in Canada have taken steps towards developing injection combinations for knee pain, such as osteoarthritis. In Canada, 25% suffer from knee osteoarthritis, which increases the clinical outcome of the Viscosupplementation treatment. The availability of Viscosupplementation treatment in many hospitals and drugs in the local stores also helps to raise market growth. Nuvo Pharmaceuticals Inc., a Canadian company, launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada to treat pain relief and improve joint functionality in patients with degenerative knee diseases.

KEY MARKET PLAYERS

Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Ferring B.V., Seikagaku Corporation, Chungai Pharmaceutical Co., Ltd., OrthogenRx Inc., and Mylan N.V. are expected to play the leading role in the U.S. viscosupplementation market.

MARKET SEGMENTATION

This research report on the U.S. viscosupplementation market is segmented and sub-segmented into the following categories.

 By Product

• Single Injection
• Three Injection
• Five Injection

 By End-Use

• Hospitals
• Orthopedic Clinic/ Ambulatory Surgical Centers (ASCs)

 By Country

• The United States